Compare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 22.4 14.3 156.0% View Chart
P/BV x 5.4 2.4 229.1% View Chart
Dividend Yield % 0.9 0.4 210.3%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
GLENMARK PHARMA
Mar-19
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,720712 382.2%   
Low Rs1,660484 343.3%   
Sales per share (Unadj.) Rs697.9349.6 199.6%  
Earnings per share (Unadj.) Rs96.132.8 293.2%  
Cash flow per share (Unadj.) Rs117.344.3 264.5%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.10.3 341.1%  
Book value per share (Unadj.) Rs515.2198.6 259.4%  
Shares outstanding (eoy) m119.57282.17 42.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.7 183.6%   
Avg P/E ratio x22.818.2 125.0%  
P/CF ratio (eoy) x18.713.5 138.6%  
Price / Book Value ratio x4.33.0 141.3%  
Dividend payout %26.06.1 426.3%   
Avg Mkt Cap Rs m261,879168,625 155.3%   
No. of employees `00014.312.0 119.1%   
Total wages/salary Rs m15,05520,561 73.2%   
Avg. sales/employee Rs Th5,822.68,196.0 71.0%   
Avg. wages/employee Rs Th1,050.51,708.1 61.5%   
Avg. net profit/employee Rs Th802.0768.5 104.4%   
INCOME DATA
Net Sales Rs m83,44498,655 84.6%  
Other income Rs m1,0422,081 50.1%   
Total revenues Rs m84,486100,736 83.9%   
Gross profit Rs m14,73415,858 92.9%  
Depreciation Rs m2,5283,259 77.6%   
Interest Rs m6513,346 19.4%   
Profit before tax Rs m12,59811,335 111.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1,1053,756 29.4%   
Profit after tax Rs m11,4939,250 124.3%  
Gross profit margin %17.716.1 109.8%  
Effective tax rate %8.833.1 26.5%   
Net profit margin %13.89.4 146.9%  
BALANCE SHEET DATA
Current assets Rs m54,96066,968 82.1%   
Current liabilities Rs m32,43340,211 80.7%   
Net working cap to sales %27.027.1 99.5%  
Current ratio x1.71.7 101.8%  
Inventory Days Days8083 95.5%  
Debtors Days Days7281 88.9%  
Net fixed assets Rs m32,71033,322 98.2%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m61,36855,770 110.0%   
Net worth Rs m61,60756,052 109.9%   
Long term debt Rs m1,59235,738 4.5%   
Total assets Rs m99,433132,888 74.8%  
Interest coverage x20.44.4 464.1%   
Debt to equity ratio x00.6 4.1%  
Sales to assets ratio x0.80.7 113.0%   
Return on assets %12.29.5 128.8%  
Return on equity %18.716.5 113.0%  
Return on capital %21.017.8 117.7%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06162,998 25.5%   
Fx outflow Rs m2,48322,859 10.9%   
Net fx Rs m13,57840,140 33.8%   
CASH FLOW
From Operations Rs m5,85113,242 44.2%  
From Investments Rs m-7,414-6,990 106.1%  
From Financial Activity Rs m792-7,387 -10.7%  
Net Cashflow Rs m-731-2,971 24.6%  

Share Holding

Indian Promoters % 66.9 48.3 138.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 6.9 479.7%  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 56,727 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PROCTER & GAMBLE HEALTH  ELDER PHARMA  SUVEN LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS